- Home
- Equipment
- switzerland
- t cells
Show results for
Refine by
T Cells Equipment Supplied In Switzerland
10 equipment items found
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
The SVLP approach, with its modular and flexible design, the inherent adjuvant properties and other immune system activators, lends itself to the development of particle-based vaccines against cancer: SVLPs displaying cancer antigens are optimally presented to the immune system and trigger cytotoxic T-cell activation in vitro and in vivo. Virometix is currently ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
It is also approved for the treatment of paediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis (GCA) and CAR-T cell-induced cytokine release syndrome (CRS). Actemra/RoActemra is available in both subcutaneous (SC) and intravenous (IV) ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on tumor bulk, CD123 expression has been ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
A multicenter Phase 2 trial of SL-701 in adult patients with second-line glioblastoma multiforme (GBM) has been completed, and data suggest that SL-701 is generating a target-specific CD8+ T-cell response, which may be translating into improved clinical outcomes, including improved overall survival, in a subset of patients. Given the safety and efficacy data ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. ...
by:Redbiotec AG based inSchlieren, SWITZERLAND
Redbiotec specializes in developing high-quality vaccines to fight difficult diseases. After successfully spinning out the CMV vaccine program that was acquired by Pfizer, Redbiotec is currently developing HSV-2 therapeutic vaccine ...
Manufactured by:Precision For Medicine, Inc. based inFrederick, MARYLAND (USA)
PBMCs are a vital component to understanding human immune function and disease response. Variability in quality, availability, and purity can derail a research study. At Precision for Medicine, PBMCs are collected and processed within our FDA-registered facility to ensure optimal cell yields, viability, and quality. ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our patented Beta-carboline derivative (ACB1801) is an actin dynamic modulator which induces cellular F-actin network remodeling (tumor reversal); this in turn translates into immuno-competency that allows the immune system to recognize tumor cells and thereby enhances the efficacy of checkpoint-inhibitor immune therapy. Immune checkpoint-inhibitors directly target the immune system of the body ...
Manufactured by:Thermo Fisher Scientific based inWaltham, MASSACHUSETTS (USA)
Invitrogen TrueCut HiFi Cas9 Protein is a high fidelity CRISPR Cas9 protein variant engineered to demonstrate superior off-target profiles, while preserving maximum on-target editing efficiency. TrueCut HiFi Cas9 Protein is ideal for applications that are sensitive to off-target events and when more precise editing is ...